Beijing Leadman Biochemistry Co.,Ltd.

XSEC:300289 Stock Report

Market Cap: CN¥2.5b

Beijing Leadman BiochemistryLtd Past Earnings Performance

Past criteria checks 0/6

Beijing Leadman BiochemistryLtd's earnings have been declining at an average annual rate of -5.1%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 0.2% per year.

Key information

-5.1%

Earnings growth rate

0.6%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate0.2%
Return on equity-0.1%
Net Margin-1.8%
Next Earnings Update28 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Beijing Leadman BiochemistryLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300289 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24403-718937
30 Jun 24423-119338
31 Mar 24448419537
31 Dec 234621519537
30 Sep 23504-6721632
30 Jun 23559-6422435
31 Mar 23623-6023334
01 Jan 23706-5623335
30 Sep 226922820337
30 Jun 226933319134
31 Mar 226402818733
01 Jan 225642218433
30 Sep 21561-2725631
30 Jun 21541-3125731
31 Mar 21531-2924437
31 Dec 20472-5123138
30 Sep 20478116843
30 Jun 20440-815647
31 Mar 20454-1517047
31 Dec 19515617948
30 Sep 19493-1019749
30 Jun 195631019745
31 Mar 196002819643
31 Dec 186554019640
30 Sep 187117816940
30 Jun 186637115255
31 Mar 186347514246
31 Dec 175767314437
30 Sep 175387915225
30 Jun 17532751720
31 Mar 17521681800
31 Dec 16533701810
30 Sep 166181261690
30 Jun 166391441750
31 Mar 166601601610
31 Dec 156821571670
30 Sep 156821411770
30 Jun 156411331660
31 Mar 156071311650
31 Dec 145371281490
30 Sep 14373801160
30 Jun 14363911090
31 Mar 14342991010

Quality Earnings: 300289 is currently unprofitable.

Growing Profit Margin: 300289 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300289 is unprofitable, and losses have increased over the past 5 years at a rate of 5.1% per year.

Accelerating Growth: Unable to compare 300289's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300289 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).

Return on Equity

High ROE: 300289 has a negative Return on Equity (-0.14%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 09:23
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Leadman Biochemistry Co.,Ltd. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Shanshan LiChina Merchants Securities Co. Ltd.
Tong ZhangChina Merchants Securities Co. Ltd.